ASPERGILLUS EIA
GALACTOMANNAN TEST

• Test Code

  309

• CPT Code

  87305

• Clinical Significance

  The aspergillus EIA test is an aid in the early diagnosis of invasive aspergillosis. In conjunction with other diagnostic tests and clinical signs of disease, it is an aid in the effective early treatment of disease.

• Methodology
  • Platelia™ Aspergillus EIA immunoenzymatic sandwich microplate assay, cleared by the FDA for the detection of galactomannan in serum or BALF.
  • Test validated at MiraVista Diagnostics for CSF specimens.
• Limitations

  The result is not intended to be used as the sole means for clinical diagnosis or patient management decisions.

  False positives can be caused by:

  • Piperacillin-tazobactam, amoxicillin/clavulanic acid
  • PLASMA-LYTE and other fluids containing sodium gluconate
  • Infection with Penicillium, Alternaria, Paecilomyces, Fusarium, Histoplasma and Blastomyces, or airway colonization with above organisms

  *Antifungal therapy may cause false negative results in patients with aspergillosis

• Specimen Collection
  • Serum: Collect serum specimens in serum separator or red top tube. Allow blood to clot for 30 minutes, then centrifuge. Pipette serum into a plastic screw cap vial.

  • CSF/BAL: Submit CSF and BAL in a sterile screw cap container.
• Minimum Specimen Requirements

  Serum/Plasma/CSF/BAL: 0.8 mL

• Specimen Stability
  • Room Temperature: 48 hours
  • Refrigerated: 5 days
  • Frozen: 5 months
• Specimen Rejection

  If specimen is too viscous to pipette

• Transport Temperature

  Refrigerated/ Frozen

• Shipping

  Ship on dry ice or frozen packs for next day service. Monday – Friday delivery.

• Turnaround Time

  Serum/CSF/BAL: Same Day

  *New positives my require confirmation

• Reference Range

  Negative

• Interpretative Information

  Negative: <0.5

  Results are reported as numeric values (Index) which are interpreted as positive or negative

• Additional Information

  Platelia™ is a registered trademark of BioRad